Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/7/2022 | Outperform → Mkt Perform | William Blair | |
| 12/20/2021 | $12.00 → $10.00 | Outperform | SVB Leerink |
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
4 - Aptinyx Inc. (0001674365) (Issuer)
8-K - Aptinyx Inc. (0001674365) (Filer)
8-K - Aptinyx Inc. (0001674365) (Filer)
25-NSE - Aptinyx Inc. (0001674365) (Subject)
SC 13G/A - Aptinyx Inc. (0001674365) (Subject)
SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
SC 13D/A - Aptinyx Inc. (0001674365) (Subject)
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Aptinyx Inc. (NASDAQ:APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an analysis of the data from the first 100 patients enrolled in its Phase 2b clinical study of NYX-783 50 mg in patients with post-traumatic stress disorder (PTSD). The study was halted in February prior to its completion in support of the company's preservation of capital. In the analysis, NYX-783 did not demonstrate sufficient improvement on the study's primary endpoint to support continued advancement of the development program by Aptinyx. In March, Aptinyx engaged Ladenburg Thalmann as its exclusive fi
NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives The company will terminate its ongoing study of NYX-783 in PTSD and analyze the data available to date Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2 clinical study evaluating the effects of NYX-458 in patients with cognitive impairment associated with Parkinson's disease and dementia with Lewy bodies. Across the overall study population, NYX-
Tentarix Biotherapeutics today announced the appointment of Andrew Kidd, MD, as chief executive officer. Mr. Kidd joins Tentarix with a distinguished career of over two decades of executive and biotech experience. He was most recently the president and CEO of Aptinyx (NASDAQ:APTX), a clinical-stage CNS-focused biotech company. His previous experience includes senior leadership roles at Baxter International (NYSE:BAX) and The Boston Consulting Group. "We are excited to welcome Andy to the Tentarix team at this critical inflection point for the company," said Tentarix Chairman Donald Santel. "Under Andy's leadership, we are poised to effectively execute on our existing partnered programs wi
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O'Neill, M.B., M.M.Sc., to the company's board of directors. Dr. O'Neill currently serves as chief medical officer and executive vice president of research and development at Sarepta Therapeutics. "Gilmore brings an exceptional background of experience and leadership to the Aptinyx board of directors," said Norbert Riedel, Ph.D., chief executive officer of Aptinyx. "His expertise in research and clinical development is amplified by the successful development programs he has overseen across a rang
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the election of Joan W. Miller, M.D., to the company's Board of Directors. Dr. Miller currently serves as the David Glendenning Cogan Professor of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School, as well as Chief of Ophthalmology at both Massachusetts Eye and Ear and Massachusetts General Hospital, and Ophthalmologist-in-Chief at Brigham and Women's Hospital. "We are delighted to welcome Joan to the Aptinyx Board of Directors," said Norbert Riedel, Ph.D., chief executive offic
William Blair downgraded Aptinyx from Outperform to Mkt Perform
SVB Leerink reiterated coverage of Aptinyx with a rating of Outperform and set a new price target of $10.00 from $12.00 previously
JP Morgan downgraded Aptinyx from Neutral to Underweight
Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use disorder $67 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the third quarter of 2022 and provided key business updates across the company's clinical-stage pipeline of novel NMDA receptor
Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 8, 2022 at 5:00 p.m. ET to report third quarter 2022 financial results and discuss recent business highlights. To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144. A live audio webcast of the event will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx'
Company expects to report results from Phase 2b study of NYX-2925 in fibromyalgia in August Data from Phase 2 study of NYX-458 in cognitive impairment expected in 1Q 2023 IND cleared for NIH grant-funded evaluation of NYX-783 in opioid use disorder $85 million cash balance provides operational runway into 2024 and enables readouts from multiple Phase 2 studies Management to host conference call today at 5:00 p.m. ET Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the